Britain approves Pfizer-BioNTech shot for younger children
Reuters2021-12-22
LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.
The country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.
The children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.